Last reviewed · How we verify
MSK-DA01
At a glance
| Generic name | MSK-DA01 |
|---|---|
| Sponsor | BlueRock Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease (PHASE3)
- Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSK-DA01 CI brief — competitive landscape report
- MSK-DA01 updates RSS · CI watch RSS
- BlueRock Therapeutics portfolio CI